Updated Phase Ib data showed safety issues due to complement activation, but Pfizer is confident the benefits outweigh the risks and monitoring systems will help as it moves into Phase III.
Pfizer Inc. will begin enrolling boys with Duchenne muscular dystrophy in a Phase III clinical trial in the second half of 2020, despite serious cases of complement activation in boys treated with the experimental gene therapy in Phase Ib.
Pfizer will initiate a Phase III clinical trial testing its gene therapy PF-06939926 in the second half of 2020 with...
The gene therapy developer appointed a new president, chief medical officer and chief of staff following the closing of its acquisition by private equity firms Carlysle and SK Capital.
The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.
A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
